Биологическая активность
TAK-994 is an oral, селективный OX2R агонист developed by Takeda for the treatment of narcolepsy type 1 (with cataplexy) and type 2 (without cataplexy). The molecule follows Takeda’s previous clinical molecule, TAK-925 (danavorexton), which was the first OX2R агонист to be tested in people with NT1 but had poor oral bioavailability and was administered intravenously in the clinic.
Оригинал на английском
TAK-994 is an oral, selective OX2R agonist developed by Takeda for the treatment of narcolepsy type 1 (with cataplexy) and type 2 (without cataplexy). The molecule follows Takeda’s previous clinical molecule, TAK-925 (danavorexton), which was the first OX2R agonist to be tested in people with NT1 but had poor oral bioavailability and was administered intravenously in the clinic.
Химические свойства
- CAS №
- 2861934-86-1
- Брутто-формула
- C₄₄H₅₆F₆N₄O₁₁S₂
- Мол. масса
- 995.06 г/моль
- SMILES
- S(C)(N[C@H]1CCN(C(C(C)(C)O)=O)[C@H]1CC1C=CC=C(C2C=C(C=C(C=2)F)F)C=1F)(=O)=O.S(C)(N[C@H]1CCN(C(C(C)(C)O)=O)[C@H]1CC1C=CC=C(C2C=C(C=C(C=2)F)F)C=1F)(=O)=O.O.O.O
- Синонимы
- TAK-994; FIRAZOREXTON SESQUIHYDRATE; 2861934-86-1; TAK-994 SESQUIHYDRATE; UG2P1IR7L3
3D-структура молекулы
Вращайте мышью · Колесо — масштаб
Хранение и физические свойства
- Условия хранения
- 2 года -20°C порошок, 2 недели 4°C в ДМСО, 6 мес. -80°C в ДМСО
Безопасность и документация
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.